Table 1. Associations between clinico-pathological criteria in breast cancer samples across the five cohorts included in the meta-analysis.
| Cohort I | Cohort II | Cohort III | Cohort IV | Cohort V | |
|---|---|---|---|---|---|
| N | 290 | 1214 | 492 | 112 | 1169 |
| Characteristics | |||||
| Treated with tamoxifen | 140 (48%) | 445 (37%) | 157 (32%) | 67 (60%) | 840 (72%) |
| FKBPL histoscore | |||||
| Median (IQR) | 187 (122–200) | 180 (165–200) | 200 (150–200) | 156 (117–200) | 200 (150–200) |
| Low | 146 (50%) | 728 (60%) | 216 (44%) | 76 (68%) | 400 (34%) |
| High | 144 (50%) | 486 (40%) | 276 (56%) | 36 (32%) | 769 (66%) |
| Tumor size | |||||
| < 20 mm | 100 (34%) | 592 (49%) | 306 (62%) | 30 (27%) | 417 (36%) |
| >= 20 mm | 189 (65%) | 615 (50%) | 186 (38%) | 60 (53%) | 712 (61%) |
| Unknown | 1 (1%) | 7 (1%) | 0 | 22 (20%) | 40 (3%) |
| Tumor grade | |||||
| 1 | 34 (12%) | 211 (17%) | 123 (25%) | 6 (6%) | 253 (22%) |
| 2 | 112 (39%) | 412 (34%) | 203 (41%) | 38 (34%) | 494 (42%) |
| 3 | 140 (48%) | 584 (48%) | 165 (33%) | 51 (46%) | 414 (35%) |
| Unknown | 4 (1%) | 7 (1%) | 1 (1%) | 17 (15%) | 8 (1%) |
| Nodal status | |||||
| Negative | 81 (28%) | 639 (53%) | 279 (57%) | 44 (39%) | 801 (68.5%) |
| Positive | 207 (71%) | 442 (36%) | 161 (33%) | 41 (37%) | 367 (31.4%) |
| Unknown | 2 (1%) | 133 (11%) | 52 (10%) | 27 (24%) | 1 (0.1%) |
| ER status | |||||
| Negative | 99 (34%) | 287 (24%) | 73 (15%) | 28 (25%) | 294 (25%) |
| Positive | 141 (49%) | 891 (73%) | 419 (85%) | 69 (62%) | 845 (72%) |
| Unknown | 50 (17%) | 36 (3%) | 0 | 15 (13%) | 30 (3%) |
| PR status | |||||
| Negative | 88 (30%) | 458 (38%) | 157 (32%) | 39 (35%) | 245 (21%) |
| Positive | 150 (52%) | 687 (56%) | 335 (68%) | 53 (47%) | 898 (77%) |
| Unknown | 52 (18%) | 69 (6%) | 0 | 20 (18%) | 26 (2%) |
| HER2 status | |||||
| Not-amplified | 198 (68%) | 1031 (85%) | 438 (89%) | 50 (45%) | 812 (69%) |
| Amplified | 64 (22%) | 162 (13%) | 42 (9%) | 10 (9%) | 135 (12%) |
| Unknown | 28 (10%) | 21 (2%) | 12 (2%) | 52 (46%) | 222 (19%) |
| Triple negative | 50 (17%) | 192 (16%) | 39 (8%) | 13 (12%) | 64 (5%) |
| KI67 | |||||
| Not amplified | 111 (38%) | 0 | 175 (36%) | 0 | 519 (44%) |
| Amplified | 151 (52%) | 0 | 286 (58%) | 0 | 610 (52%) |
| Unknown | 28 (10%) | 1214 (100%) | 31 (6%) | 112 (100%) | 40 (4%) |
Abbreviations: PR-progesterone receptor, ER-estrogen receptor, HER2- receptor tyrosine-protein kinase erbB-2, IQR – Interquartile range